A recent study published in the Proceedings of the National Academy of Sciences (PNAS) reveals that a novel three-drug combination therapy can effectively induce lasting regression of pancreatic tumors in both mice and human tumor-derived models. This therapy targets three critical survival pathways: Kirsten rat sarcoma viral oncogene homolog (KRAS), Epidermal Growth Factor Receptor (EGFR), and Signal Transducer and Activator of Transcription 3 (STAT3). Researchers found that while targeting individual pathways was insufficient, simultaneous inhibition led to significant tumor regression and prevented treatment resistance. In genetically engineered mouse models, the triple therapy resulted in complete tumor disappearance within 3 to 4 weeks, with no recurrence observed for up to 300 days. The study highlights the importance of STAT3 in driving treatment resistance, as its activation was linked to tumor survival. The combination therapy, which includes daraxonrasib, afatinib, and SD36, demonstrated a strong safety profile with no major adverse effects. These promising results indicate that a multi-targeted approach could represent a significant advancement in treating pancreatic ductal adenocarcinoma, although further clinical validation is necessary.